Opus Genetics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
Opus Genetics, Inc. (IRD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $2.64 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-22.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2013-03-22
- Opus Genetics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2011-12-31 was $0.00.
- Opus Genetics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2011-09-30 was $0.00.
- Opus Genetics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2012 was $2.64M, a 9.82% decline from fiscal 2011.
- Opus Genetics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2011 was $2.92M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2012-12-31 | $2.64M 10-K · filed 2013-03-22 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | $0.00 derived: sum of 2 quarters · filed 2013-03-22 | $2.92M 10-K · filed 2013-03-22 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $2.92M 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | $2.92M 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |